PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION
Objective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were olmesartan/lercanidipine and zofenopril/lercanidipine in patients with essential hypertension II-III stage.Materials and methods. The authors performed prospective randomized uncontrolled study. Were exami...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2017-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394459357216768 |
|---|---|
| author | D. S. Kaskaeva M. M. Petrova O. V. Zimnitskaya |
| author_facet | D. S. Kaskaeva M. M. Petrova O. V. Zimnitskaya |
| author_sort | D. S. Kaskaeva |
| collection | DOAJ |
| description | Objective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were olmesartan/lercanidipine and zofenopril/lercanidipine in patients with essential hypertension II-III stage.Materials and methods. The authors performed prospective randomized uncontrolled study. Were examined in 27 people essential hypertension with II-III stage age from 40 to 71 years before and after the use of combinations of drugs olmesartan/lercanidipine and zofenopril/lercanidipine. An ABC/VEN-analysis, сost-effectiveness analysis, comparative assessment of the incidence of side effects of the studied drugs were performed.Results. Anti-hypertensive effect of the studied combinations of drugs were not significantly different and equally effectively reduced blood pressure. But the cost of blood pressure reduction at 1 mm Hg was the smallest in the group zofenopril/lercanidipine.Conclusion. The results of pharmacoeconomic analysis to be more cost-effective combination for the treatment of patients with essential hypertension II-III stage is the combination of zofenopril/lercanidipine. |
| format | Article |
| id | doaj-art-1ff1f6ae280641448ec7c1d8cf6ec95b |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2017-03-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-1ff1f6ae280641448ec7c1d8cf6ec95b2025-08-20T03:39:58ZrusIRBIS LLCФармакоэкономика2070-49092070-49332017-03-01943810.17749/2070-4909.2016.9.4.003-008147PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSIOND. S. Kaskaeva0M. M. Petrova1O. V. Zimnitskaya2Krasnoyarsk State Medical University named after Professor V. F. Voino-YasenetskyKrasnoyarsk State Medical University named after Professor V. F. Voino-YasenetskyKrasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky Regional state budgetary healthcare institution Regional clinical hospitalObjective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were olmesartan/lercanidipine and zofenopril/lercanidipine in patients with essential hypertension II-III stage.Materials and methods. The authors performed prospective randomized uncontrolled study. Were examined in 27 people essential hypertension with II-III stage age from 40 to 71 years before and after the use of combinations of drugs olmesartan/lercanidipine and zofenopril/lercanidipine. An ABC/VEN-analysis, сost-effectiveness analysis, comparative assessment of the incidence of side effects of the studied drugs were performed.Results. Anti-hypertensive effect of the studied combinations of drugs were not significantly different and equally effectively reduced blood pressure. But the cost of blood pressure reduction at 1 mm Hg was the smallest in the group zofenopril/lercanidipine.Conclusion. The results of pharmacoeconomic analysis to be more cost-effective combination for the treatment of patients with essential hypertension II-III stage is the combination of zofenopril/lercanidipine.https://www.pharmacoeconomics.ru/jour/article/view/162pharmacoeconomic analysisсost-effectiveness analysishypertensionolmesartanzofenoprillercanidipinecerabc/ven-analysis. |
| spellingShingle | D. S. Kaskaeva M. M. Petrova O. V. Zimnitskaya PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Фармакоэкономика pharmacoeconomic analysis сost-effectiveness analysis hypertension olmesartan zofenopril lercanidipine cer abc/ven-analysis. |
| title | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION |
| title_full | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION |
| title_fullStr | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION |
| title_full_unstemmed | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION |
| title_short | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION |
| title_sort | pharmacoeconomic study of olmesartan lercanidipine and ofenopril lercanidipine combinations in the treatment of patients with essential hypertension |
| topic | pharmacoeconomic analysis сost-effectiveness analysis hypertension olmesartan zofenopril lercanidipine cer abc/ven-analysis. |
| url | https://www.pharmacoeconomics.ru/jour/article/view/162 |
| work_keys_str_mv | AT dskaskaeva pharmacoeconomicstudyofolmesartanlercanidipineandofenoprillercanidipinecombinationsinthetreatmentofpatientswithessentialhypertension AT mmpetrova pharmacoeconomicstudyofolmesartanlercanidipineandofenoprillercanidipinecombinationsinthetreatmentofpatientswithessentialhypertension AT ovzimnitskaya pharmacoeconomicstudyofolmesartanlercanidipineandofenoprillercanidipinecombinationsinthetreatmentofpatientswithessentialhypertension |